ARS Pharmaceuticals: Still A Buy As Neffy Access Improves

ARS Pharmaceuticals is scaling Neffy, its needle-free epinephrine spray, with expanded focus on CVS Caremark, Medicaid, retail affordability, and a larger sales force to improve access by 2H2026. Neffy is already generating commercial revenue, and the key investment test is whether repeat sales accelerate as distribution improves. The piece is positive on the setup for SPRY, but it is still an execution story rather than a major near-term catalyst.

Analysis

SPRY’s setup is less about first-fill demand and more about conversion from trial to habit: the key variable is whether access friction falls fast enough to turn episodic prescriptions into repeat usage. That makes payer wins and retail affordability more important than headline scripts, because the market will likely pay up only if refill velocity starts to show up in the next 2-3 quarters. If repeat rate improves, the operating leverage is meaningful given the fixed-cost nature of the commercial push; if it does not, the company risks burning promotional dollars to expand a funnel that never compounds.

The second-order winner is the distribution stack, not just SPRY. CVS Caremark and Medicaid access improvements can shift volume toward channels with lower abandonment and fewer out-of-pocket shocks, which should also pressure competing rescue therapies and any adjacent emergency-allergy products that rely on less convenient delivery. A broader sales force matters most in underpenetrated physician offices and allergist networks, but the real unlock is downstream: more stable payer coverage can make prescribers more willing to switch patients from legacy options without fearing a rejected claim at the pharmacy counter.

The main contrarian point is that the market may be underestimating how lumpy this category can be. Severe-allergy products often look like a chronic prescription story in models, but utilization can remain event-driven and refill economics can disappoint if patients perceive it as a just-in-case purchase rather than a must-replace item. The bull case is intact, but it likely needs two clean readouts: improving access data by mid-2026 and visible repeat purchase behavior before investors should extrapolate a durable growth curve.

Tail risk is execution slippage or a reimbursement reset that delays the access ramp by 6-9 months, which would force the equity to re-rate on cash burn rather than growth optionality. Near term, the stock should trade on quarterly evidence of pharmacy pickup, abandonment rates, and any commentary on refill conversion; over a 12-18 month horizon, the thesis either compounds into a platform story or stalls as a niche launch.

Key Decisions for Investors

• Long SPRY on pullbacks into earnings: use a 3-6 month horizon and size for binary commercial-execution risk; upside is a multiple expansion if refill metrics inflect, while downside is limited by the market already recognizing launch optionality.
• Buy SPRY call spreads dated 6-9 months out to express improving access without paying full volatility: target a structure that monetizes a gradual rerating if 2H2026 access progress starts to show earlier in the data.
• If you own SPRY, add a stop-rule: reduce 25-50% if next two quarters fail to show improving repeat-fill or pharmacy conversion trends; this is a conversion story, not a pure launch story.
• Relative-value: long SPRY vs. short a higher-multiple healthcare commercialization name with weaker near-term catalyst visibility; the better risk/reward is in names where access improvement can quickly translate into recurring revenue.